ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, usual dosage and administration, relative contraindications, clinically significant drug interactions, adverse drug reactions and overdosage of Mesoridazine. Mesoridazine is excreted into breast milk. Avoid prescribing mesoridazine pharmacotherapy to women who are breast-feeding. If mesoridazine pharmacotherapy is required, breast-feeding probably should be discontinued. Prescribe mesoridazine pharmacotherapy cautiously to patients who have histories of heart disease. Collaboration with the patient’s cardiologist is indicated. Additional precautions have been advised for patients who require mesoridazine and other phenothiazine pharmacotherapy. Caution patients who are receiving mesoridazine pharmacotherapy against performing activities that require alertness, judgment, and physical coordination until their response to mesoridazine is known. Mesoridazine pharmacotherapy commonly has been associated with drowsiness, sedation, and other ADRs related to its anticholinergic actions. Signs and symptoms of mesoridazine overdosage include agitation, confusion, delirium, and drowsiness. Mesoridazine overdosage requires emergency symptomatic medical support of body systems with attention to increasing mesoridazine elimination.
